Topiramate indications and usage

Jump to navigation Jump to search
Topiramate
TOPIRAMATE® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Topiramate
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information about topiramate, click here.

Indications and Usage

Topiramate tablets USP are an antiepileptic (AED) agent indicated for:

Monotherapy epilepsy: Initial monotherapy in patients ≥10 years of age with partial onset or primary generalized tonic-clonic seizures.

Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients ≥2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) .

  • Topiramate is most frequently prescribed for, the prevention of migraines. This drug is also widely used to treat migraines due to the effect it has on the blood vessels in the brain. It is used as a preventative for atypical migraine sufferers. It widens the blood vessels in the brain which become restricted by increased serotonin levels. It has been found to be increasingly effective for migraine sufferers with limited side effects.[1]
  • Bipolar disorder,[2] and indicate that it may have mood stabilizing properties.[3] In 2006, a Cochrane review concluded that there is insufficient evidence on which to base any recommendations regarding the use of topiramate in any phase of bipolar illness.[4] Another meta-analysis published in the Lancet demonstrated that topiramate was of no significant benefit in the treatment of bipolar mania.[5]
  • Sometimes use topiramate to augment psychotropics, or to counteract the weight gain associated with numerous antidepressants.
  • A more recent Cochrane review, published in 2010, suggested a benefit of topiramate in the treatment of symptoms of borderline personality disorder, however the authors note that this was based only on one randomized controlled trial and requires replication. Also the Authors noted that the long-term effects have not been studied.[6][7][8]

This drug has been investigated for use in:

  • A pilot study suggested that topiramate is effective against infantile spasms.[17]

Off-label and investigational uses

  • Topiramate is also being studied with a mixture of phentermine to form a drug called Qsymia for the treatment of obesity.

On May 21, 2010, Ortho-McNeil pled guilty and was fined $6.14 million by the FDA for promoting Topamax to treat psychiatric disorders without applying for any Federal government approval. Also, there were no data from any well-controlled clinical trial to demonstrate that Topamax was safe and/or effective to treat any psychiatric conditions at all.[23][24]

References

  1. ↑ Kececi, Hulusi; Atakay, Selcuk (2009). "Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients". Journal of Clinical Neuroscience. 16 (12): 1588. doi:10.1016/j.jocn.2009.03.025. PMID 19793661.
  2. ↑ Arnone, D (2005). "Review of the use of Topiramate for treatment of psychiatric disorders". Annals of general psychiatry. 4 (1): 5. doi:10.1186/1744-859X-4-5. PMC 1088011. PMID 15845141.
  3. ↑ Letmaier, M; Schreinzer, D; Wolf, R; Kasper, S (2001). "Topiramate as a mood stabilizer". International clinical psychopharmacology. 16 (5): 295–8. doi:10.1097/00004850-200109000-00008. PMID 11552774.
  4. ↑ Vasudev, Kamini; MacRitchie, Karine; Geddes, John; Watson, Stuart; Young, Allan H; Young, Allan H (2006). Young, Allan H, ed. "Topiramate for acute affective episodes in bipolar disorder". Cochrane database of systematic reviews (Online) (1): CD003384. doi:10.1002/14651858.CD003384.pub2. PMID 16437453.
  5. ↑ PMID 21851976 (PMID 21851976)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  6. ↑ Leib, Klaus; Völlm, Birgit; Rücker, Gerta; Timmer, Antje; Stoffers, Jutta M (2010). "Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials". British Journal of Psychiatry. 196 (1): 4–12. doi:10.1192/bjp.bp.108.062984. PMID 20044651.
  7. ↑ do Prado-Lima PA, Kristensen CH, Bacaltchuck J (April 2006). "Can childhood trauma predict response to topiramate in borderline personality disorder?". J Clin Pharm Ther. 31 (2): 193–6. doi:10.1111/j.1365-2710.2006.00716.x. PMID 16635055.
  8. ↑ Clinical trial number NCT00685178 for "Clinical Trial of Topiramate for Cocaine Addiction" at ClinicalTrials.gov
  9. ↑ Johnson, BA; Ait-Daoud, N; Bowden, CL; Diclemente, CC; Roache, JD; Lawson, K; Javors, MA; Ma, JZ (2003). "Oral topiramate for treatment of alcohol dependence: a randomised controlled trial". Lancet. 361 (9370): 1677–85. doi:10.1016/S0140-6736(03)13370-3. PMID 12767733.
  10. ↑ 10.0 10.1 Johnson, BA; Rosenthal, N; Capece, JA; Wiegand, F; Mao, L; Beyers, K; McKay, A; Ait-Daoud, N; Anton, RF (2007). "Topiramate for treating alcohol dependence: a randomized controlled trial". JAMA: the Journal of the American Medical Association. 298 (14): 1641–51. doi:10.1001/jama.298.14.1641. PMID 17925516.
  11. ↑ "Medication can help recovering meth addicts stay sober, study finds". Retrieved 2012-06-13.
  12. ↑ Van Ameringen, M; Mancini, C; Pipe, B; Campbell, M; Oakman, J (2002). "Topiramate treatment for SSRI-induced weight gain in anxiety disorders". The Journal of clinical psychiatry. 63 (11): 981–4. doi:10.4088/JCP.v63n1104. PMID 12444810.
  13. ↑ Wilding, J; Van Gaal, L; Rissanen, A; Vercruysse, F; Fitchet, M; Obes-002 Study, Group (2004). "A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects". International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 28 (11): 1399–410. doi:10.1038/sj.ijo.0802783. PMID 15486569.
  14. ↑ Shapira, NA; Goldsmith, TD; McElroy, SL (2000). "Treatment of binge-eating disorder with topiramate: a clinical case series". The Journal of clinical psychiatry. 61 (5): 368–72. doi:10.4088/JCP.v61n0508. PMID 10847312.
  15. ↑ McElroy, SL; Arnold, LM; Shapira, NA; Keck Jr, PE; Rosenthal, NR; Karim, MR; Kamin, M; Hudson, JI (2003). "Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial". The American Journal of Psychiatry. 160 (2): 255–61. doi:10.1176/appi.ajp.160.2.255. PMID 12562571.
  16. ↑ Berlant, J; Van Kammen, DP (2002). "Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report". The Journal of clinical psychiatry. 63 (1): 15–20. doi:10.4088/JCP.v63n0104. PMID 11838620.
  17. ↑ Glauser, TA; Clark, PO; Strawsburg, R (1998). "A pilot study of topiramate in the treatment of infantile spasms". Epilepsia. 39 (12): 1324–8. doi:10.1111/j.1528-1157.1998.tb01331.x. PMID 9860068.
  18. ↑ Follett, PL; Deng, W; Dai, W; Talos, DM; Massillon, LJ; Rosenberg, PA; Volpe, JJ; Jensen, FE (2004). "Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate". Journal of Neuroscience. 24 (18): 4412–20. doi:10.1523/JNEUROSCI.0477-04.2004. PMID 15128855.
  19. ↑ Hoopes, SP; Reimherr, FW; Hedges, DW; Rosenthal, NR; Kamin, M; Karim, R; Capece, JA; Karvois, D (2003). "Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures". The Journal of clinical psychiatry. 64 (11): 1335–41. doi:10.4088/JCP.v64n1109. PMID 14658948.
  20. ↑ Khazaal, Y; Cornuz, J; Bilancioni, R; Zullino, DF (2006). "Topiramate for smoking cessation". Psychiatry and clinical neurosciences. 60 (3): 384–8. doi:10.1111/j.1440-1819.2006.01518.x. PMID 16732758.
  21. ↑ Celebisoy, N; Gökçay, F; Sirin, H; Akyürekli, O (2007). "Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study". Acta neurologica Scandinavica. 116 (5): 322–7. doi:10.1111/j.1600-0404.2007.00905.x. PMID 17922725.
  22. ↑ Láinez, MJ; Pascual, J; Pascual, AM; Santonja, JM; Ponz, A; Salvador, A (2003). "Topiramate in the prophylactic treatment of cluster headache". Headache. 43 (7): 784–9. doi:10.1046/j.1526-4610.2003.03137.x. PMID 12890134.
  23. ↑ "Ortho-McNeil Pharmaceutical, LLC Pleads Guilty to Illegal Promotion of Topamax". FDA website. 2010-05-21. Retrieved 2010-05-25.
  24. ↑ [http//dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32b48ea0-a215-43b8-83b4-a5435a686d68 "TOPIRAMATE (TOPIRAMATE ) TABLET, FILM COATED [AUROBINDO PHARMA LIMITED]"] Check |url= value (help). Retrieved 6 February 2014.

Template:Antimigraine preparations

Retrieved from "https://www.wikidoc.org/index.php?title=Topiramate_indications_and_usage&oldid=940560"